HCV Archives – Page 16 of 31 – Treatment Action Group

US Health & Human Services (HHS) Strategic Plan FY 2018-2022: TAG Comments to the Assistant Secretary for Planning and Evaluation

October 27, 2017
Chad Cipiti

TAG comments submitted to the Strategic Planning Team at the Office of the Assistant Secretary for Planning and Evaluation regarding the HHS Strategic Plan FY 2018-2022. The HHS Strategic Plan should set a precedent for reducing the burden of disease nationally through its focus on access to affordable treatment, advancement of research, implementation of evidence-based interventions, expansion of populations served, and inclusion of all stakeholders.

TAG Letter to House E&C Committee Opposing “Right to Try” Bills

October 3, 2017
Chad Cipiti

TAG’s comments to the Health Subcommittee of the U.S. House of Representatives Energy and Commerce Committee, in association with its hearing, “Examining Patient Access to Investigational Drugs,” and the deliberations of H.R. 1020, the Compassionate Freedom of Choice Act of 2017, and S. 204, the Right to Try Act of 2017.

Hepatitis C Treatment Access in Prisons: Legal and Policy Challenges

October 2, 2017
Chad Cipiti

On Monday, October 2, 2017, Treatment Access Group joined National Viral Hepatitis Roundtable and the Hepatitis Education Project to present this update on HCV DAA treatment access in the U.S. prison system. The webinar included information about newly available treatments,…

TAG Applauds Malaysian Government’s Decision to Make Generic form of Life-Saving Hep C Cure

September 20, 2017
Chad Cipiti

The Government of Malaysia reaffirmed its commitment to affordable access to hepatitis C treatment by issuing a compulsory license on sofosbuvir (Sovaldi).

TAG’s Annual Pipeline Report: Promising New HIV, TB & HCV Drugs and Diagnostics

July 18, 2017
Chad Cipiti

Treatment Action Group (TAG) announces the launch of its annual research and development landscape analysis: The Pipeline Report: Drugs, Diagnostics, Vaccines, Preventive Technologies, Research Toward a Cure, and Immune-Based and Gene Therapies in Development.

HCV Pipeline: DAAs and Diagnostics in the Pangenotypic Era

July 5, 2017
Chad Cipiti

July 2017 By Annette Gaudino INTRODUCTION The continued development of direct-acting antivirals (DAAs) against hepatitis C virus (HCV) has brought both multigenotypic and pangenotypic regimens to market, with more on the horizon. These simpler-to- prescribe regimens potentially eliminate the need…

TAG Earns Coveted 4-Star Rating from Charity Navigator

June 6, 2017
Chad Cipiti

TAG’s strong financial health and commitment to accountability and transparency have earned it a 4-star rating from Charity Navigator, America’s largest independent charity evaluator.

House to People Living with HIV, HCV and TB: “Drop Dead”

May 4, 2017
Chad Cipiti

Statement condemning passage of the American Health Care Act (AHCA) today by the House of Representatives and calls for critical community action as the dangerous bill now heads to Senate.

Health Affairs Blog Post Highlights Fair Pricing Coalition Recommendations to Modernize and Strengthen Existing Laws to Control Drug Costs

March 31, 2017
Chad Cipiti

With growing bipartisan support for feasible measures to control skyrocketing prescription medication costs, a Health Affairs Blog post published today describes four proposals to strengthen and modernize cost control measures that already exist in the United States.

HIV, TB, HCV, Global Health and Research Communities Call on Congress to Protect the Fogarty International Center

March 30, 2017
Chad Cipiti

Dear Majority Leader McConnell, Minority Leader Schumer, Speaker Ryan, and Democratic Leader Pelosi: We the undersigned urge Congress to reject devastating funding cuts to the National Institutes of Health (NIH) proposed under the President’s Fiscal Year (FY) 2018 “skinny budget,” released on March 16, 2017. Of grave concern is the targeted elimination of the Fogarty International Center at NIH. This indiscriminate cut jeopardizes life-saving research required to end devastating global diseases like tuberculosis (TB) and HIV/AIDS, as well as malaria, dengue, and Ebola.